Ketamine for Depression: How It Works (2024) [video]

Original Article ↗ Hacker News Discussion ↗

Personal experiences with ketamine & psychedelics

  • Several posters describe clinical ketamine (IV or esketamine) as unpleasant acutely but “miraculous” or strongly beneficial for depression/anxiety afterward, often after multiple sessions.
  • Others report strong but different effects from psilocybin “hero doses,” including identity dissolution, vivid synesthesia, confronting childhood/parental anxiety, and lasting relief from existential depression plus better emotional self-observation.
  • Some find psychedelics (LSD/shrooms/DMT) spiritually intense but not lasting; others say lasting change depends on dose, set/setting, integration, and sometimes microdosing.
  • People note that ketamine’s subjective “trip” is distinct from classic psychedelics and can feel more like being steered or dissociated than guided.

Risks, addiction, and unsafe combinations

  • Multiple comments warn about ketamine addiction and long-term personality/mind changes, citing real-world examples and historical figures.
  • Strong debate over combining ketamine with MDMA: some describe dangerous “overdoses” (psychologically overwhelming, not necessarily medically critical), others demand citations and emphasize careful dosing.
  • DXM is discussed as “baby ketamine,” with some users praising its mood “afterglow,” others criticizing casual recommendations of very high OTC doses and dangerous combos (e.g., with diphenhydramine).
  • Warnings against self-medicating: suggestions to read a widely-circulated suicide note related to long-term psychedelic use; concerns about MDMA every weekend leading to prolonged depression.

Ketamine, SSRIs, and other treatments

  • Comparisons between ketamine/psychedelics and SSRIs get heated:
    • One side stresses severe, sometimes persistent SSRI side effects and argues psychedelics can be safer when properly supervised.
    • Others push back, arguing risks for both are nontrivial and data is incomplete; emphasize matching patients to treatments with lowest tail-risk.
  • TMS and combined ketamine+TMS are reported as helpful for some, ineffective for others.
  • Treatment-resistant depression and hippocampal atrophy are mentioned; debate over whether neuroplasticity drugs can compensate for structural loss.

Access, legality, and clinical vs DIY use

  • Clinical psilocybin in Oregon is reported around $3,500/session; some see that as absurd vs cheap “street” shrooms, others note you’re paying for specialized therapists, overhead, and legal safety.
  • Some prefer home/retreat “set and setting” with trusted sitters over sterile clinics; others stress finding cautious medical professionals who don’t over-sell treatments.
  • Confusion about drug scheduling appears; commenters clarify ketamine is Schedule III (in the U.S.) and legally prescribed.

Culture & advocacy debates

  • One participant criticizes “psychedelic advocates” for allegedly framing use as a mark of enlightenment, making social pressure likely; others say most scenes are explicitly non-coercive and emphasize consent and safety.
  • There’s broad agreement that psychedelics are powerful tools, not magic cures, and can be very harmful for some people or in the wrong context.

Adjunct & alternative ideas

  • Suggestions for resistant cases include: psychedelic-assisted therapy, MDMA in loving group settings, re-checking diagnoses (e.g., ADHD, autism, medical causes), and even MRI to rule out structural issues.
  • Non-drug approaches raised: cold exposure, engaging work/social obligation, gut microbiome support via fermented foods, and standard psychotherapy.

Mechanism & future directions

  • A paper is cited suggesting many antidepressants (including ketamine and classic psychedelics) act via TrkB, the BDNF receptor.
  • This raises hope for future drugs that boost neuroplasticity like psychedelics but without hallucinations.